ArticleInternational journal of molecular sciences2019
CB2 Receptor Stimulation and Dexamethasone Restore the Anti-Inflammatory and Immune-Regulatory Properties of Mesenchymal Stromal Cells of Children with Immune Thrombocytopenia.
Article in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 23 citations in OpenAlex.
- Trial
- Mesenchymal stem cells therapy for immune thrombocytopenia in pregnancy: a case report.BMC pregnancy and childbirth · 2025Article
- CB2 and TRPV1 receptors in inflammatory state of macrophages from sickle cell anemia pediatric/young adults.Scientific reports · 2025Article
- Underlying disease is the main risk factor in post-splenectomy complication risk: Data from a national database.British journal of haematology · 2025Article
- Effects of CB2 Receptor Modulation on Macrophage Polarization in Pediatric Inflammatory Bowel Disease.International journal of molecular sciences · 2025Article
- Long-term outcomes of avascular necrosis in sickle cell disease using joint-specific patient-reported outcome measures: Results from a multicentre study.British journal of haematology · 2025Article
- Study on the Treatment of ITP Mice with IVIG Sourced from Distinct Sex-Special Plasma (DSP-IVIG).International journal of molecular sciences · 2023Article
- Therapeutic potential of MSCs and MSC-derived extracellular vesicles in immune thrombocytopenia.Stem cell research & therapy · 2023Review
- CB2 Receptor as Emerging Anti-Inflammatory Target in Duchenne Muscular Dystrophy.International journal of molecular sciences · 2023Article
- Pretreated Mesenchymal Stem Cells and Their Secretome: Enhanced Immunotherapeutic Strategies.International journal of molecular sciences · 2023Review
- Knowledge mapping of immune thrombocytopenia: a bibliometric study.Frontiers in immunology · 2023Article
- Effects of CB2 Receptor Modulation on Macrophage Polarization in Pediatric Celiac Disease.Biomedicines · 2022Article
- Eltrombopag in paediatric immune thrombocytopenia: Iron metabolism modulation in mesenchymal stromal cells.British journal of haematology · 2022Article
- Bone marrow mesenchymal stem cell-derived exosomes induce the Th17/Treg imbalance in immune thrombocytopenia through miR-146a-5p/IRAK1 axis.Human cell · 2021Article
- Cannabinoid receptor 2 plays a central role in renal tubular mitochondrial dysfunction and kidney ageing.Journal of cellular and molecular medicine · 2021Article
- Pharmacological Properties, Therapeutic Potential and Molecular Mechanisms of JWH133, a CB2 Receptor-Selective Agonist.Frontiers in pharmacology · 2021Review
- Cannabinoids in Medicine: Cancer, Immunity, and Microbial Diseases.International journal of molecular sciences · 2020Review
- Effects of Eltrombopag on In Vitro Macrophage Polarization in Pediatric Immune Thrombocytopenia.International journal of molecular sciences · 2020Article
- Cannabinoid Receptor Type 2: A Possible Target in SARS-CoV-2 (CoV-19) Infection?International journal of molecular sciences · 2020Review
- The Endocannabinoid System in Pediatric Inflammatory and Immune Diseases.International journal of molecular sciences · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by antibody-mediated platelet destruction, with a complex and unclear pathogenesis. The impaired immunosuppressive capacity of mesenchymal stromal cells in ITP patients (ITP-MSCs) might play a role in the development of the disease. Correcting the MSC defects could represent an alternative therapeutic approach for ITP. High-dose dexamethasone (HD-Dexa) is the mainstay of the ITP therapeutic regimen, although it has several side effects. We previously demonstrated a role for cannabinoid receptor 2 (CB₂) as a mediator of anti-inflammatory and immunoregulatory properties of human MSCs. We analyzed the effects of CB₂ stimulation, with the selective agonist JWH-133, and of Dexa alone and in combination on ITP-MSC survival and immunosuppressive capacity. We provided new insights into the pathogenesis of ITP, suggesting CB₂ receptor involvement in the impairment of ITP-MSC function and confirming MSCs as responsive cellular targets of Dexa. Moreover, we demonstrated that CB₂ stimulation and Dexa attenuate apoptosis, via Bcl2 signaling, and restore the immune-modulatory properties of MSCs derived from ITP patients. These data suggest the possibility of using Dexa in combination with JWH-133 in ITP, reducing its dose and side effects but maintaining its therapeutic benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.